Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Genetics of Multiple Myeloma in Latin America

Blood (2022) 140 (Supplement 1): 13112–13113.

https://doi.org/10.1182/blood-2022-169600

Published: 2022

Journal Articles

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, Arleigh McCurdy, Heather J. Sutherland, Martha L Louzada, Christopher P. Venner, Hira S Mian, Rami Kotb, Ibraheem Othman, Fernando Camacho, Engin Gul, Donna E. Reece, Darrell J White, Molei Fu

Blood (2021) 138 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2021-147101

Published: 2021

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD FRCPC, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Arleigh McCurdy, MD BSc, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Rami Kotb, MD, Darrell J White, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Anthony Reiman, MD, Fernando Camacho, PhD, Molei Fu, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-141087

Published: 2020

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD, Nizar Bahlis, MD, Christopher P. Venner, Arleigh McCurdy, MD, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Darrell J White, MD, Rami Kotb, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Tony Reiman, MD, Fernando Camacho, Julia Dobbin, Molei Fu, Engin Gul, BS, MBA, Donna E Reece, MD

Blood (2019) 134 (Supplement_1): 3121.

https://doi.org/10.1182/blood-2019-124457

Published: 2019

Journal Articles

New US Myeloma Registry (Connect MM® – The Multiple Myeloma Disease Registry): Features of Newly Diagnosed Patients In 2010

Brian G. M. Durie, MD, Jatin J. Shah, BS, MD, Rafat Abonour, MD, Cristina Gasperetto, MD, Jayesh Mehta, MD, Chris L. Pashos, PhD, Kathleen Toomey, MD, Mohit Narang, MD, Howard Terebelo, DO, Fernando Camacho, MD, Arlene S. Swern, PhD, Thomas K. Street, RPh, Kristen A. Sullivan, MBA, Robert M. Rifkin, MD

Blood (2010) 116 (21): 5032.

https://doi.org/10.1182/blood.V116.21.5032.5032

Published: 2010

Journal Articles

Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.

Donna E. Reece, MD, Faraz Zaman, MD, Young Trieu, MSc, Giovanni Piza Rodriguez, MD, Bruno Teixeira, HBSc, Kim Yoong, BSc, Phm, Fernando Camacho, PhD, Richard K Plante, MSc

Blood (2009) 114 (22): 4892.

https://doi.org/10.1182/blood.V114.22.4892.4892

Published: 2009

Journal Articles

Bortezomib [VELCADE™], Pegylated Liposomal Doxorubicin [DOXIL/CAELYX®] and Dexamethasone in the Treatment of Previously Untreated Multiple Myeloma Patients: Impact on Quality-of-Life.

Andrew Belch, MD, Donna E. Reece, MD, Nizar J. Bahlis, MD, Darrell White, MD, Bruno Teixeira, HBSc, Fernando Camacho, PHD, Richard K. Plante, MSc

Blood (2007) 110 (11): 3618.

https://doi.org/10.1182/blood.V110.11.3618.3618

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Genetics of Multiple Myeloma in Latin America

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

New US Myeloma Registry (Connect MM® – The Multiple Myeloma Disease Registry): Features of Newly Diagnosed Patients In 2010

Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.

Bortezomib [VELCADE™], Pegylated Liposomal Doxorubicin [DOXIL/CAELYX®] and Dexamethasone in the Treatment of Previously Untreated Multiple Myeloma Patients: Impact on Quality-of-Life.

Email alerts

ASH Publications

American Society of Hematology

Update search

Genetics of Multiple Myeloma in Latin America

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

New US Myeloma Registry (Connect MM® – The Multiple Myeloma Disease Registry): Features of Newly Diagnosed Patients In 2010

Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.

Bortezomib [VELCADE™], Pegylated Liposomal Doxorubicin [DOXIL/CAELYX®] and Dexamethasone in the Treatment of Previously Untreated Multiple Myeloma Patients: Impact on Quality-of-Life.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only